Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
magazineClinigen reveals strategy in bid to become the Amazon of hard-to-access drugs
Clinigen (CLIN:AIM)
Gain to date: 0.1%
Original entry point: Buy at 865p, 11 October 2018
We are flummoxed by speciality pharma firm Clinigen’s (CLIN:AIM) lack of share price momentum as it pursues an ambitious strategy in a bid to become the Amazon of hard-to-access medicines.
An investor presentation late last month saw the company outline plans to drive growth of its unlicensed medicines via its Cliniport online platform.
Cliniport could become a vital platform for healthcare professionals by helping them discover over 400 speciality medicines, as well as find drugs that are currently at risk of shortage.
The platform can also help find alternative medicines for specific diseases and boost knowledge around unlicensed drugs, which comprised 45% of Clinigen’s profit last year.
Numis analyst Stefan Hamill says growing Cliniport into a scalable e-commerce platform for hard-to-access medicines could drive future traction and earnings upgrades, but concedes there is ‘much to do’.
Clinigen also told attendees of its investor day that it had achieved $1m in cross-selling since buying packaging and distribution services group CSM in October, with a further $1m of sales pending.
Numis forecasts Clinigen will achieve £85.9m pre-tax profit in the year to June 2019, rising to £104.1m in 2020.
Important information:
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
